How to buy Amgen (AMGN) stocks

Amgen is a drug manufacturers - general business based in the US. Amgen shares (AMGN) are listed on the NASDAQ and all prices are listed in US Dollars.

Its last market close was $316.04 – an increase of 0.74% over the previous week. Amgen employs 28,000 staff and has a trailing 12-month revenue of around $33.4 billion.

Our top picks for where to buy Amgen stock

Buy Amgen stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Amgen stock price (NASDAQ: AMGN)

Use our graph to track the performance of AMGN stocks over time.

Amgen stocks at a glance

• Key figures

Information last updated 2025-03-20.

Latest market close	$316.04
52-week range	$251.27 - $338.98
50-day moving average more info button	$295.43
200-day moving average more info button	$306.57
Wall St. target price	$315.95
PE ratio more info button	41.672
Dividend yield more info button	$9 (3.02%)
Earnings per share (TTM) more info button	$7.56

Is it a good time to buy Amgen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Is Amgen stock undervalued or overvalued?

Valuing Amgen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amgen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Amgen's P/E ratio

Amgen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, Amgen shares trade at around 42x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stock or simply that they're over-valued.

Amgen's PEG ratio

Amgen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0685. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amgen's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Amgen's EBITDA

Amgen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $15.2 billion.

The EBITDA is a measure of a Amgen's overall financial performance and is widely used to measure a its profitability.

Amgen financials

Revenue TTM	$33.4 billion
Operating margin TTM	51.81%
Gross profit TTM	$23 billion
Return on assets TTM	6.4%
Return on equity TTM	67.55%
Profit margin	12.24%
Book value	$10.95
Market Capitalization more info button	$169.2 billion

TTM: trailing 12 months

Amgen stock dividends

Dividend payout ratio: 46.06% of net profits

Recently Amgen has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Amgen shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Amgen's case, that would currently equate to about $9 per share.

While Amgen's payout ratio might seem fairly standard, it's worth remembering that Amgen may be investing much of the rest of its net profits in future growth.

Amgen's most recent dividend payout was on 5 June 2025. The latest dividend was paid out to all shareholders who bought their stocks by 15 May 2025 (the "ex-dividend date").

Have Amgen's stocks ever split?

Amgen's stocks were split on a 2:1 basis on 21 November 1999 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Amgen stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for Amgen stocks, which in turn could have impacted Amgen's stock price.

Amgen stock price volatility

Over the last 12 months, Amgen's stocks have ranged in value from as little as $251.27 up to $338.9803. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amgen's is 0.524. This would suggest that Amgen's stocks are less volatile than average (for this exchange).

Amgen overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Amgen is owned by insiders or institutions?
Currently 0.218% of Amgen stocks are held by insiders and 82.062% by institutions. How many people work for Amgen?
Latest data suggests 28,000 work at Amgen. When does the fiscal year end for Amgen?
Amgen's fiscal year ends in December. Where is Amgen based?
Amgen's address is: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 What is Amgen's ISIN number?
Amgen's international securities identification number is: US0311621009 What is Amgen's CUSIP number?
Amgen's Committee on Uniform Securities Identification Procedures number is: 031162100

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.